Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combination Study of Guadecitabine and Pembrolizumab. (HyPeR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02998567
Recruitment Status : Active, not recruiting
First Posted : December 20, 2016
Last Update Posted : November 17, 2020
Sponsor:
Collaborators:
Astex Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.
Institute of Cancer Research, United Kingdom
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

Tracking Information
First Submitted Date  ICMJE November 2, 2016
First Posted Date  ICMJE December 20, 2016
Last Update Posted Date November 17, 2020
Actual Study Start Date  ICMJE January 26, 2017
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 16, 2016)
  • Establish maximum tolerated dose (MTD) [ Time Frame: 12 months ]
    To establish a maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of the combination of guadecitabine and pembrolizumab in patients with advanced solid tumours. To determine the maximum dose at which no more than 1 of 6 patients at the same dose level experience a drug related toxicity (DLT), as defined in section 3.1.4 of the protocol.
  • Measure Adverse Events according to CTCAE v4.0 [ Time Frame: 24 months ]
    To assess the safety and toxicity profile of the combination of guadecitabine and pembrolizumab. To determine causality and grading severity of each adverse event by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 20, 2016)
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Transcriptome analysis in whole bloods using the PAXgene assay.
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Targeted sequencing in plasma circulating free DNA.
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    White blood cell analysis by flow cytometry.
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    DNA methylation analysis in blood peripheral blood mononuclear cells (PBMC).
  • Pharmacodynamic studies in guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Immunohistochemistry of immune cell in serial biopsies.
  • Pharmacodynamic studies in guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    DNA methylation analysis in serial biopsies.
  • Pharmacodynamic studies in guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Transcriptome analysis in serial biopsies.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 16, 2016)
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Transcriptome analysis in whole bloods using PAXgene.
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Targeted sequencing in plasma circulating free DNA.
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    White blood cell analysis by flow cytometry.
  • Pharmacodynamic profile of guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    DNA methylation analysis in blood PBMC.
  • Pharmacodynamic studies in guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Immunohistochemistry of immune cell in serial biopsies.
  • Pharmacodynamic studies in guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    DNA methylation analysis in serial biopsies.
  • Pharmacodynamic studies in guadecitabine in combination with pembrolizumab. [ Time Frame: 24 months ]
    Transcriptome analysis in serial biopsies.
Current Other Pre-specified Outcome Measures
 (submitted: December 16, 2016)
Preliminary assessment of the anti-tumour activity [ Time Frame: 24 months ]
Target lesions will be measured according to RECIST v1.1 criteria.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Combination Study of Guadecitabine and Pembrolizumab.
Official Title  ICMJE HyPeR: A Phase 1 Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation Hypo-Methylating Agent in Combination With Pembrolizumab (MK3475) in Patients With Refractory Solid Tumours
Brief Summary HyPeR is a multi-centre Phase 1 Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation Hypo-Methylating Agent in Combination with Pembrolizumab (MK3475) in Patients with Refractory Solid Tumours. The investigators will be investigating the safety and toxicity of the combination.
Detailed Description

This is a phase I trial of the combination of the hypo-methylating agent guadecitabine and an anti-PD1 antibody (anti- programmed cell death protein 1) pembrolizumab. Patients will receive subcutaneous guadecitabine daily on Days 1-4 of each 21-day cycle. Patients will receive pembrolizumab intravenously once per 21-day cycle: on Day 8 of Cycle 2 and on Day 1 of each cycle from Cycle 3 onwards.

The rational for this design is that this pre-loading with Guadecitabine will sensitise the tumour to Pembrolizumab through the re-expression of genes that enhance tumour recognition, the increase in density of tumour infiltrating T-cells and stimulation of the adaptive immune response.

In Part A (Dose Escalation) the investigators will investigate escalating doses of Guadecitabine in combination with Pembrolizumab. Patients with advanced solid tumours will be recruited in cohorts of 3 to 6 patients to investigate the combination of 200 mg of pembrolizumab, administered as an intravenous injection, with escalating doses of guadecitabine, administered via a subcutaneous injection, once a day for 4 days (Days 1-4). Guadecitabine dosing will start at 45mg/m2 but can be decreased to 30mg/m2 in the event of toxicities or increased to 60mg/m2 in the absence of toxicities. Once the maximum tolerated dose is reached (or under the advice from the Safety Review Committee) patients will be enrolled to the dose expansion phase (Part B).

Part B (Dose Expansion): 20 patients will be recruited to Part B to further explore the safety and activity of the combination of guadecitabine and pembrolizumab. This cohort will include, but not be limited to patients with: castration resistant prostate cancer (CRPC), non-small cell lung cancer (NSCLC) and possibly other solid tumours based on emerging anti-tumour activity data from Part A and any other relevant preclinical or clinical published data.

Approximately 30 to 35 patients will be entered into this trial, 6 to 12 patients in Part A and 20 patients in Part B.

The anticipated accrual rate of the dose escalation phase will involve approximately 3 patients per month across 2 centres. Accrual rates could be higher or lower but this estimate takes into consideration that the first patient on an escalation cohort should complete Cycle 2 Day 15 prior to accrual of further patients in the cohort. Accrual in the expansion phase is estimated at 2-4 patients per month across 2 centres. It is expected that the duration of recruitment will be 12-24 months.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Condition  ICMJE
  • Castration-Resistant Prostatic Cancer
  • Non Small Cell Lung Cancer
Intervention  ICMJE
  • Drug: Guadecitabine
    In arm 1 (escalation) and 2 (expansion).
  • Drug: Pembrolizumab
    In arm 1 (escalation) and 2 (expansion).
Study Arms  ICMJE
  • Experimental: Escalation
    Fixed dose of Pembrolizumab with escalating dose of Guadecitabine to establish the phase 2 recommended dose.
    Interventions:
    • Drug: Guadecitabine
    • Drug: Pembrolizumab
  • Experimental: Expansion
    Continuation of the Guadecitabine and Pembrolizumab dose established in arm 1: expansion in the recommended patient population.
    Interventions:
    • Drug: Guadecitabine
    • Drug: Pembrolizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: January 21, 2020)
34
Original Estimated Enrollment  ICMJE
 (submitted: December 16, 2016)
35
Estimated Study Completion Date  ICMJE June 2021
Estimated Primary Completion Date June 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Histologically or cytologically confirmed advanced solid tumours, refractory to conventional treatment, or for which no conventional therapy exists or is declined by the patient.
  2. Life expectancy of at least 12 weeks.
  3. Eastern Co-operative Oncology Group (ECOG) performance status of 0-1 with no significant deterioration over the previous 2 weeks (Appendix 1).
  4. Evaluable or measurable disease as assessed by RECIST 1.1.
  5. Haematological and biochemical indices within the ranges shown below. These measurements must be performed within one week (Day -7 to Day 1) prior to administration of any investigational medicinal product.

    • Haemoglobin (Hb) ≥ 9.0 g/dL
    • Absolute neutrophil count ≥ 1.5 x 109/L
    • Platelet count ≥ 100 x 109/L
    • International normalised ratio (INR) ≤ 1.5x upper limit of normal (ULN)

Or:

Prothrombin time ≤ 1.5x upper limit of normal (ULN)

- Serum bilirubin ≤1.5x ULN

Or:

Direct bilirubin (for patients with total bilirubin >1.5x ULN) ≤ 1.5x ULN

  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5x ULN (for patients with liver metastases ≤ 5x ULN is permissible)
  • Calculated creatinine clearance (per institutional standard) ≥ 50 mL/min 6.18 years or over. 7. Written (signed and dated) informed consent and be capable of co-operating with treatment and follow-up.

    8. Agree to the use of archival paraffin embedded tissue (if available) for PD-L1 (programmed death-ligand 1) analysis 9. Agree to provide a fresh tumour biopsy at baseline and on Cycle 2 Day 8 of a tumour lesion not previously irradiated (tumours progressing in a prior site of radiation are allowed for PD-L1 characterization, other exceptions may be considered after consultation with the Chief Investigator).

    10. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 14 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

    11. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 6 months after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year. Decitabine, a metabolite of Guadecitabine, can affect fertility and so oocyte cryopreservation should be discussed with female patients.

    12. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy. Decitabine, a metabolite of Guadecitabine, can affect fertility and so cryopreservation of sperm should be discussed with male patients.

Exclusion Criteria:

  1. Radiotherapy (except brief course for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas, Mitomycin-C and 4 weeks for investigational medicinal products) before treatment, except for hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for medical castration in patients with CRPC, which are permitted.
  2. Patient has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ bladder or cervical cancer that has undergone potentially curative therapy.
  3. Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment.
  4. Ongoing toxic manifestations of previous treatments. Exceptions to this are:

    • Grade 1 toxicities, which in the opinion of the investigator should not exclude the patient
    • Alopecia of any grade
  5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 14 days prior to the first dose of trial treatment. The use of physiologic doses of corticosteroids may be approved after consultation with the chief Investigator.
  6. Has an active autoimmune disease that has required systemic treatment in past 3 months (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with Sjogren's syndrome will not be excluded from the study. In addition patients that experienced a Grade 2 or higher immune-related AE's on treatment with immunotherapy will be excluded from the study.
  7. Has evidence of interstitial lung disease.
  8. Has a history of (non-infectious) pneumonitis that required steroid treatment or has active pneumonitis. Pneumonitis includes acute interstitial pneumonitis, pneumonitis and idiopathic pneumonia syndrome.
  9. Active infection, requiring systemic therapy.
  10. Has received a live vaccine within 30 days of planned start of study therapy. Note: The killed virus vaccines used for seasonal influenza vaccines for injection are allowed; however intranasal influenza vaccines (e.g. FluMist®) are live attenuated vaccines and are not allowed.
  11. Major surgery (excluding minor procedures, e.g. placement of vascular access) from which the patient has not yet recovered.
  12. At high medical risk because of severe or uncontrolled non-malignant systemic disease including active uncontrolled infection, active bleeding diathesis.
  13. Known to be serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Screening for chronic conditions is not required.
  14. Any of the following cardiac criteria:

    • Mean resting corrected QT interval (QTc) > 470 msec obtained from 3 consecutive electrocardiograms (ECGs) within 5 minutes of each other.
    • Any clinically significant abnormalities in rhythm, conduction or morphology of resting ECG, e.g. complete left bundle branch block, third degree heart block.
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval
    • Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association [NYHA Grade 2 (refer to Appendix 4)]
    • Uncontrolled hypertension - Systolic BP >160mmHg and/or diastolic BP >100mmHg
    • Left ventricular ejection fraction (LVEF) below institutional lower limit of normal.
  15. History of hypersensitivity to active or inactive excipients of guadecitabine or pembrolizumab or drugs with a similar chemical structure or class to either agent.
  16. Is a participant or plans to participate in another interventional clinical trial, whilst taking part in this Phase I study of guadecitabine and pembrolizumab. Participation in an observational trial would be acceptable.
  17. Any other condition which in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02998567
Other Study ID Numbers  ICMJE CCR4420
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Royal Marsden NHS Foundation Trust
Study Sponsor  ICMJE Royal Marsden NHS Foundation Trust
Collaborators  ICMJE
  • Astex Pharmaceuticals, Inc.
  • Merck Sharp & Dohme Corp.
  • Institute of Cancer Research, United Kingdom
Investigators  ICMJE Not Provided
PRS Account Royal Marsden NHS Foundation Trust
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP